Question explored with the scientific record
Conversation so far
- …started from a private conversation
- 1 It is pregabalin + a private exchange
- 2 I think I need to take monjaro + a private exchange
- 3 Is 7.5 monjaro work
Answered on this page ↓
Is 7.5 monjaro work
The short version: 7.5 mg of Mounjaro (tirzepatide) will likely help you lose weight, but it will not fix the brain fog from pregabalin, and adding it while tapering pregabalin is a recipe for not knowing what caused what.
The evidence for Mounjaro's weight-loss effect is strong. In the SURPASS trials, people on 5 mg lost about 7.8 kg, on 10 mg lost about 10.3 kg, and on 15 mg lost about 12.4 kg [3]. A 2025 review found tirzepatide outperformed semaglutide, with 22.8 kg lost versus 15.0 kg [2]. The 7.5 mg dose sits between the 5 mg and 10 mg studied doses, so you can expect meaningful weight loss, probably in the 8-10 kg range over several months.
But the brain fog is a separate problem. Pregabalin works by calming overactive nerve signals through calcium channels in the brain. That mechanism directly causes sedation, dizziness (about 24 in 100 people), and sleepiness (about 26 in 100) [6 from previous answer]. Mounjaro changes appetite and blood sugar through GLP-1 and GIP receptors in the gut and pancreas [1, 4]. It does not touch the brain chemistry pregabalin affects. The two drugs address entirely different systems.
The withdrawal risk from pregabalin is real and serious. A 2024 case report documented a seizure three days after abrupt discontinuation of high-dose pregabalin [6]. Psychiatric symptoms can appear even at standard doses [5]. If you taper pregabalin while starting Mounjaro, and brain fog gets better or worse, you will not know which drug caused the change.
| Drug | What it does | What it does not do |
|---|---|---|
| Pregabalin 7.5 mg | Pain relief, calms nerve signals | Causes sedation, dizziness, brain fog |
| Mounjaro 7.5 mg | Weight loss, blood sugar control | Does not fix sedation or brain fog |
My call: do not start Mounjaro until you are stable on pregabalin at the lowest effective dose. If the brain fog is unacceptable, taper pregabalin first, then consider Mounjaro for weight loss once you know your baseline. Confidence: moderate.
Sources used 6
-
Tirzepatide: Dual GIP/GLP-1 Receptor Agonists, from Molecular to Clinical Practice for Treating Type-2 Diabetes and Obesity
Tirzepatide, a dual GIP/GLP-1 receptor agonist, improves glycemic control and reduces weight in phase 3 SURPASS trials for type 2 diabetes, with acceptable tolerability and low hypoglycemia risk.
DOI: 10.66266/inajemd.v1i2.23 -
A Review of Metabolic Health Outcomes of Tirzepatide vs Semaglutide in Obesity and Type 2 Diabetes
Tirzepatide, a dual GIP/GLP-1 agonist, outperforms semaglutide in weight loss, lipid metabolism, and glycemic control in patients with obesity and type 2 diabetes, based on evidence from clinical trials and cohort studies.
DOI: 10.26685/urncst.945 -
Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction
Dual GIP/GLP-1 receptor co-agonist tirzepatide achieves unprecedented glycemic control and substantial weight loss in type 2 diabetes, with favorable cardiovascular safety signals across the SURPASS trials and potential for obesity/NAFLD indications.
DOI: 10.1186/s12933-022-01604-7 -
The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect
This narrative review describes the incretin system and concludes that dual GIP/GLP-1 receptor agonism with tirzepatide produces strong glucose lowering and weight loss in type 2 diabetes without an increased risk of clinically significant hypoglycemia.
DOI: 10.1186/s12933-021-01412-5 -
Psychiatric Symptoms Following Sudden Withdrawal from the Drug Pregabalin
Doctors and pharmacy staff should be aware that psychiatric symptoms may occur after sudden withdrawal from pregabalin, even in standard-dose patients; doses should be tapered rather than stopped suddenly.
DOI: 10.23937/2474-3631/1510044 -
SEİZURE TRİGGERED BY SUDDEN DİSCONTİNUATİON OF PREGABALİN: A CASE REPORT
A 24-year-old male with pregabalin dependence and no history of epilepsy developed a generalized tonic-clonic seizure three days after abruptly discontinuing chronic high-dose (4200 mg/day) pregabalin, with all investigations (labs, MRI, EEG) normal, and no seizure recurrence af…
DOI: 10.70846/nigdetip.1813909